$BMY outplays slow #Opdivo sales to crush first-quarter #earnings estimates. Legacy Bristol Myers products (pre-Celgene takeover) grew almost 13% in the quarter. Including Celgene, sales rocketed 82%. #pharmaceuticals #stocks #investingnews https://t.co/7AbmPDxvV3